Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says [Yahoo! Finance]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
The company's marketed medicine, Wakix (pitolisant), is approved for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. Wakix generated net revenues of $172.8 million in the second quarter of 2024, up 29% year-over-year The average number of patients on Wakix increased by approximately 250 patients sequentially to approximately 6,550 for the quarter ended June 30, 2024. UBS initiates with a Buy rating and price target of $56 on Harmony. “We like Harmony because, in our view, continued growth is feasible for Wakix,” the analyst writes. The UBS analyst models a 19% '24-'26E sales CAGR compared to a consensus of 16% and $1.2 billion peak sales from Wakix in narcolepsy. “We believe the narcolepsy market can present more opportunities as awareness of narcolepsy increases the diagnosis rate from the current ~50%,” the analyst adds. UBS also writes that Wakix is well-positioned in the polypharmacy market with its differentiated profile vs. other approve
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateAccesswire
- Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH MeetingAccesswire
- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.MarketBeat
- Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 MillionAccesswire
PTGX
Earnings
- 11/7/24 - Beat
PTGX
Sec Filings
- 11/14/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- PTGX's page on the SEC website